Angle PLC Contract Announcement With Eisai Inc.

Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701

ANGLE plc a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a contract with the global pharmaceutical company, Eisai Inc. ("Eisai").

Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.

ANGLE's Portrait HER2 assay enables quantitative assessment of both HER2 protein expression (via IF) and HER2/neu gene amplification (via FISH) to identify patients who could benefit from anti-HER2 ADC treatment. HER2-low breast cancer accounts for 55% of all breast cancer cases with analysts predicting that the global HER2+ breast cancer ADC market will reach US $3.3 billion per annum by 2030. Because of market expansion into HER2-low patients, ANGLE has developed a quantitative HER2 assay to enable accurate stratification of patient populations throughout the treatment pathway given HER2 status can change over time.

ANGLE Chief Executive Officer, Andrew Newland, commented:
"The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of genomic, transcriptomic and proteomic changes. ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible. We are delighted that Eisai is utilising our new HER2 assay for this study and believe that a successful pilot study will lead the way to major expansion of this line of our business going forward."